secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gain Therapeutics, Inc. (GANX)
CIK:        0001819411
Form:       8-K
Filed at:   2023-04-12T23:59:59+00:00
Accession:  0001104659-23-044623
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gain Therapeutics appoints C. Evan Ballantyne as CFO, effective April 10, 2023
------------------------------------------------------------------------------

- Appointment: C. Evan Ballantyne named CFO effective April 10, 2023; predecessor Salvatore Calabrese transitions.
- Compensation: $350k base salary, 40% target bonus; inducement equity of 100,000 options at $4.79 (4-year vest) and 100,000 performance RSUs.
- Performance RSUs: 50,000 vest upon extending cash runway 24 months; 50,000 vest upon stock price reaching $10.00 for 10 days VWAP.
- Background: Ballantyne was CFO of OncXerna, Orchestra BioMed, Cerecin; raised millions in equity and structured >$200M partnership.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819411/000110465923044623/0001104659-23-044623-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819411/000110465923044623/tm2312468d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-044623

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer